ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism - Fig 6

Correlation between plasma CNP immunoreactivity and growth plate thickness of lower limbs [proximal ends of femur (A) and tibia (B), and distal ends of femur (C) and tibia (D)] in rats after sc bolus injections or infusion of ASB20123 at 0, 0.005, 0.015, 0.05, 0.15, and 0.5 mg/kg/day for 7 days. Each value represents the mean ± SD of 4 or 5 rats. The horizontal axis indicates the mean plasma CNP immunoreactivity concentration at 15 min after the 1st dose for the sc bolus injection groups or mean plasma CNP immunoreactivity on the 2nd day for the sc infusion groups. The vertical axis indicates the mean percentage of growth plate thickness compared to the respective control groups. Plasma CNP immunoreactivity after sc infusion of ASB20123 at 0.005 mg/kg/day was not detected. NS: not significant (p > 0.05), *: p p < 0.01 compared to the control group (0 mg/kg/day) using Dunnett’s test (logarithm conversion).